A trio of drugmakers have issued separate recalls in the U.S. thanks to string of production flubs, including failed impurity and dissolution specifications and incorrect labelling of infusion bags. The companies in question, Dr. Reddy’s Laboratories, Sun Pharma and Zydus
read moreThe company revealed a plan to shutter the site back in March of 2022. Now, more than 150 staffers are set to lose their jobs throughout the rest of 2025 and into 2026. More: Merck plots 163 layoffs as it
read moreAstraZeneca has signed two deals worth $1.35 billion with Alteogen to development subcutaneous versions of the British pharma’s cancer drugs despite a potential patent infringement risk. More: AstraZeneca signs Alteogen deal worth up to .35B for subcutaneous cancer drugs despite
read moreNovo Nordisk has been accepted back into the fold. Two years after suspending Novo, the Association of the British Pharmaceutical Industry reinstated the Danish drugmaker after seeing “clear, significant and sustained improvements.” More: Novo Nordisk accepted back into UK pharma
read more
VIDAR-1 trial marks company’s clinical-stage debut More: Anocca announces authorisation pancreatic cancer trial Source: News
read more
Collaboration brings remote care to cancer patients More: Careology and Entia join forces to transform cancer care Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals